Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclical testosterone plus darolutamide for non-metastatic castration-resistant prostate cancer
ACTRN12624000582550Phase 2Recruiting
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of testosterone enanthate and darolutamide in prostate cancer (PCa), sponsored by ANZUP Cancer Trials Group. Primary endpoint: Metastasis-free survival. Started Dec 2024; status: recruiting.
02
Drugs
testosterone enanthatedarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12624000582550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000582550.